Trial results for a study evaluating enhanced virologic monitoring for pregnant and postpartum women with HIV were posted on ClinicalTrials.gov on 2025-08-14, showing no statistically significant reduction in viremia for the intervention group compared to controls.
Background
HIV infection, particularly in pregnant and postpartum women, requires careful management to ensure maternal health and prevent mother-to-child transmission. Achieving and maintaining viral suppression is a primary goal of HIV treatment. Interventions that support treatment adherence and provide timely feedback on viral load levels are crucial for improving outcomes in this vulnerable population. This study aimed to explore the feasibility and effectiveness of an enhanced monitoring approach, including peer counseling and rapid viral load result delivery, to improve viral suppression.
Trial design
This completed study, which did not specify a phase, enrolled 550 participants. The trial focused on individuals with HIV Infections, Viremia, and those who were Pregnancy Related. The intervention involved peer counseling about viral load levels and rapid delivery of viral load results, with the goal of supporting treatment adherence. The study evaluated the feasibility of this intervention and assessed whether it improved viral suppression, defined as plasma HIV RNA >50 copies/mL, six months following the intervention, compared to historical controls. The study compared a 'Pilot' intervention group against 'Controls - Prospectively Enrolled' and 'Controls - Abstracted From Records'.
Key results
The study measured the number of participants with plasma HIV RNA >50 copies/mL, indicating detectable viremia, at 6 months post-intervention:
- In the 'Pilot' intervention group, 34 participants had plasma HIV RNA >50 copies/mL.
- In the 'Controls - Prospectively Enrolled' group, 13 participants had plasma HIV RNA >50 copies/mL.
- In the 'Controls - Abstracted From Records' group, 15 participants had plasma HIV RNA >50 copies/mL.
Logistic regression analyses were conducted to compare the risk of viremia:
- One analysis yielded an Odds Ratio (OR) of 1.21 (95.0% Confidence Interval: 0.83 to 1.76) with a p-value of 0.33, comparing pilot participants to controls. The hypothesis was that pilot participants would have a reduced risk of viremia.
- A second analysis showed an Odds Ratio (OR) of 1.25 (95.0% Confidence Interval: 0.73 to 2.14) with a p-value of 0.41.
What this means
The posted results indicate that the enhanced virologic monitoring intervention, which included peer counseling and rapid viral load result delivery, did not achieve a statistically significant reduction in viremia (plasma HIV RNA >50 copies/mL) among pregnant and postpartum women with HIV. The odds ratios of 1.21 and 1.25, coupled with p-values of 0.33 and 0.41, suggest that the intervention did not significantly improve viral suppression compared to control groups. These findings imply that while the intervention aimed to address treatment adherence, its specific design or implementation in this pilot study did not yield the hypothesized benefit in reducing the risk of viremia. Further research into different strategies or refinements of this approach may be necessary to effectively improve viral suppression in this population.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for the study NCT05845619, titled "Enhanced Virologic Monitoring for Pregnant and Postpartum Women With HIV", were posted on 2025-08-14 on clinicaltrials.gov.